Safety and efficacy of transcatheter arterial embolization for management of refractory hematuria of prostatic origin

Q3 Medicine Journal of Interventional Medicine Pub Date : 2022-05-01 DOI:10.1016/j.jimed.2022.03.005

Jinlong Zhang , Quanyu Wang , Hongwei Zhao , Bing Yuan , Xuedong Sun , Yang Guan , Zhuting Fang , Maoqiang Wang

{"title":"Safety and efficacy of transcatheter arterial embolization for management of refractory hematuria of prostatic origin","authors":"Jinlong Zhang , Quanyu Wang , Hongwei Zhao , Bing Yuan , Xuedong Sun , Yang Guan , Zhuting Fang , Maoqiang Wang","doi":"10.1016/j.jimed.2022.03.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To estimate the safety and efficacy of transcatheter arterial embolization (TAE) in the treatment of refractory hematuria of prostatic origin (RHPO).</p></div><div><h3>Methods</h3><p>This retrospective study included 23 patients who underwent TAE for RHPO between May 2013 and August 2021. Technical and clinical success rates were calculated, and arteriogram findings and complications were detected.</p></div><div><h3>Results</h3><p>Embolization was performed 24 times in 23 patients. Technical success was achieved in 24/24 (100%) embolization procedures. Contrast agent extravasation was detected during 2 of the 24 angiographic procedures. Bilateral embolization was performed in 23 (95.8%) of the 24 procedures. The clinical success rate was 21/23 (91.3%), and hematuria stopped 1–4 days after TAE. No serious complications were observed.</p></div><div><h3>Conclusion</h3><p>TAE is a safe and effective minimally invasive technique for treating patients with RHPO.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ec/b7/main.PMC9349008.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Interventional Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2096360222000151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To estimate the safety and efficacy of transcatheter arterial embolization (TAE) in the treatment of refractory hematuria of prostatic origin (RHPO).

Methods

This retrospective study included 23 patients who underwent TAE for RHPO between May 2013 and August 2021. Technical and clinical success rates were calculated, and arteriogram findings and complications were detected.

Results

Embolization was performed 24 times in 23 patients. Technical success was achieved in 24/24 (100%) embolization procedures. Contrast agent extravasation was detected during 2 of the 24 angiographic procedures. Bilateral embolization was performed in 23 (95.8%) of the 24 procedures. The clinical success rate was 21/23 (91.3%), and hematuria stopped 1–4 days after TAE. No serious complications were observed.

Conclusion

TAE is a safe and effective minimally invasive technique for treating patients with RHPO.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

经导管动脉栓塞治疗前列腺源性难治性血尿的安全性和有效性

目的评价经导管动脉栓塞(TAE)治疗前列腺源性难治性血尿(RHPO)的安全性和有效性。方法本回顾性研究包括2013年5月至2021年8月期间接受RHPO TAE治疗的23例患者。计算技术和临床成功率，并检测动脉造影结果和并发症。结果23例患者共行24次栓塞术。24/24(100%)栓塞术技术成功。24例造影检查中有2例发现造影剂外渗。24例手术中有23例(95.8%)进行了双侧栓塞。临床成功率为21/23(91.3%)，术后1 ~ 4 d血尿停止。无严重并发症。结论tae是一种安全有效的微创治疗RHPO的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊